EMA/CO for high-risk gestational trophoblastic tumors: Results from a cohort of 272 patients
EMA/CO for high-risk gestational trophoblastic tumors: Results from a cohort of 272 patients
复制标题
DOI：
10.1200/jco.1997.15.7.2636
复制
发表时间：
1997-07-01
影响因子：
45.3
通讯作者：
Bagshawe, KD
中科院分区：
文献类型：
--
作者：
Bower, M;Newlands, ES;Bagshawe, KD
目的：评价依托泊苷、甲氨蝶呤和放线菌素与环磷酰胺和长春新碱（EMA/CO）交替化疗治疗高危妊娠滋养细胞肿瘤（GTT）的结果，并记录该方案的中期和长期毒性。患者和方法：共有272例连续高危GTT女性患者，包括121例既往治疗的患者，接受每周一次的EMA/CO治疗，中位随访时间为4.5年（范围：1 - 16年）。结果：累计5年生存率为86.2%(95%可信区间为81.9% ~ 90.5%)，EMA/CO开始后2年内未发生GTT死亡。在一个多变量模型中，不良预后因素是肝转移的存在(P
Purpose: To evaluate the results of etoposide, methotrexate, and dactinomycin alternating with cyclophosphamide and vincristine (EMA/CO) chemotherapy in women with high-risk gestational trophoblastic tumors (GTT) and to document the middle- and long-term toxicity of the regimen.Patients and Methods: A total of 272 consecutive women with high-risk GTT, including 121 previously treated patients, were treated with weekly EMA/CO, The median follow-up duration is 4.5 years (range, 1 to 16).Results: The cumulative 5-year survival rate is 86.2% (95% confidence interval, 81.9% to 90.5%), No deaths from GTT have occurred later than 2 years after the start of EMA/CO. In a multivariate model, adverse prognostic factors were the presence of liver metastases (P